A sliver of hope has emerged from a potential dengue vaccine study, as this mosquito-borne viral disease rampages across the country and sends hundreds of men, women and children to hospitals in Sri Lanka.The TAK-003 potential vaccine — which underwent testing in Sri Lanka as part of a multi-centre clinical trial — was ‘efficacious’ (successful in producing the desired effect) against virologically-confirmed dengue fever (DF) among healthy children and adolescents 4-16 years of age, irrespective of previous dengue exposure.Simply put, the potential vaccine which comes in the form of a two-dose subcutaneous injection, was “generally safe” and “well-tolerated”. It “demonstrated” protection in these children regardless of previous dengue exposure, it is understood.
